On Monday, November 4, the next meeting of the Transparency Council.
The agenda includes:
1 Prepare a position paper on the evaluation of the drug Trulicity (dulaglutidum) for the indication: type 2 diabetes in patients treated with at least two hypoglycemic drugs, with HbA1c ≥ 7.0%, obesi...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
